Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- GSK5764227: An Antibody-Drug Conjugate Targeting B7-H3 Enters Phase 1/2 Trial December 12, 2025
- MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors December 12, 2025
- Logic-gated DARPins, a Promising Advancement in Immune Therapy for Solid Tumors December 11, 2025
- CONVERT‑HB1: a Phase 2 Trial About Prostate Directed Treatment After Systemic Treatment in mHSPC December 11, 2025
GSK5764227: An Antibody-Drug Conjugate Targeting B7-H3 Enters Phase 1/2 Trial
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxGSK5764227 represents a promising advancement in treating metastatic castration-resistant prostate cancer (mCRPC). This antibody-drug conjugate targets B7-H3, a protein overexpressed on prostate cancer cells, delivering a topoisomerase I inhibitor payload directly to tumors while minimizing damage to healthy tissues. Early data from broader solid tumor studies show the drug’s monotherapy potential, with objective response rates […]
MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxMHB048C is an investigational antibody–drug conjugate designed to target prostate‑specific membrane antigen (PSMA) on tumor cells and selectively deliver a DNA topoisomerase I–inhibiting cytotoxic payload. By combining a PSMA‑directed antibody with a potent payload, the drug aims to exploit the high and relatively restricted expression of this surface antigen in advanced prostate cancer and in […]
Logic-gated DARPins, a Promising Advancement in Immune Therapy for Solid Tumors
/in Not PCa related/by MaxLogic-gated DARPins are a promising new tool in cancer treatment that could make immunotherapy safer and more effective for hard-to-treat solid tumors. They work by only turning on immune cells called T cells when two specific markers are found together on cancer cells, preventing dangerous overactivation in healthy parts of the body. What makes them […]
CONVERT‑HB1: a Phase 2 Trial About Prostate Directed Treatment After Systemic Treatment in mHSPC
/in Clinical Trial, Metastatic, Phase 2/by MaxCONVERT‑HB1 trial addresses a long‑standing uncertainty in metastatic hormone‑sensitive prostate cancer: whether aggressively treating the primary prostate tumor adds meaningful benefit for patients who already have high‑volume metastatic disease and are receiving modern intensified systemic therapy. For years, data from studies like STAMPEDE and HORRAD suggested that local treatment to the prostate might help men […]
UPDATE: ProstACT Global Phase 3 Trial for TLX591 Dosed The First Patient
/in Clinical Trial, Metastatic, Phase 3/by MaxProstACT Global is a pivotal randomized Phase 3 study testing the PSMA-targeted radiopharmaceutical TLX591 (lutetium‑177 rosopatamab tetraxetan) in metastatic castration‑resistant prostate cancer. The trial has just moved into its randomized expansion phase, with the first patient in this part dosed at a specialized prostate cancer center in Melbourne, marking a key transition from safety/dosimetry work […]
UPDATE: TD001 a New Potent ADC for Prostate Cancer Expressing PSMA Enters Phase 1/2
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxTD001, is an investigational antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), developed for the treatment of men with metastatic castration-resistant prostate cancer whose tumors express PSMA will start recruiting patients for its phase 1/2 clinical trial. Mechanistically, TD001 combines a monoclonal antibody directed against PSMA with a topoisomerase I inhibitor payload, exatecan, linked through […]
PROSTest: Blood mRNA Assay Predicts 177Lu-PSMA Success in mCRPC After One Cycle
/in Retrospective studies/by MaxA study presented at the 2025 Society of Urologic Oncology (SUO) Annual Meeting has introduced PROSTest, a novel blood-based mRNA assay that accurately predicts treatment outcomes for 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC) patients. The multi-center investigation analyzed 268 PET-positive mCRPC patients from centers in Munster, Basel, and Essen, all with median […]
REVELUTION Trial: GnRH Antagonists Show Less Coronary Plaque Progression Than Agonists in Prostate Cancer ADT
/in Clinical Trial, Metastatic, Phase 2/by MaxRelugolix showed less coronary plaque progression than leuprolide in men receiving androgen deprivation therapy with prostate cancer and pelvic radiotherapy, according to the REVELUTION trial. The prospective study enrolled 94 ADT-naïve men from June 2022 to March 2024, with 90 completing analysis across three arms: radiotherapy alone (n=28), radiotherapy plus leuprolide (n=31), and radiotherapy plus […]